Cheng Yin Pan Purchases Shares of Prenetics Global Limited

Cheng Yin Pan recently made a move in Prenetics Global Limited by purchasing 15,873 shares on June 15, 2026. This transaction took place as the stock traded at $20.75 on the NasdaqGM. The shares were acquired without a planned purchase price, reflecting Pan's confidence in the company's potential.

Other Institutional Activity in Prenetics Global Limited

Several institutional investors have been active in Prenetics Global Limited. Goldman Sachs Group Inc significantly increased its holdings by 151,338 shares, bringing its total to 193,583 shares valued at about $3.74 million. Millennium Management LLC also boosted its position, adding 141,168 shares to hold 192,600 shares worth approximately $3.72 million. Meanwhile, Wells Fargo & Company/MN expanded its stake by 81,806 shares, resulting in 84,806 shares valued at $1.64 million.

Prenetics Global Limited Stock Down 20.4%

Shares of NasdaqGM:PRE traded at $20.75. Prenetics Global Limited, with a market cap of approximately $348.7 million, operates in the healthcare sector. The stock has experienced a 52-week low of $7.05 and a high of $23.63. Its 50-day moving average is $18.21, and its 200-day moving average is $16.34. The company maintains a strong current ratio of 5.15 and a quick ratio of 4.60, with a debt-to-equity ratio of 0.38.

Recent Earnings

Prenetics Global Limited reported revenues of $120.07 million, showing growth of 7.7%. However, the company is not yet profitable, with a net margin of -41.99% and a return on equity of -40.77%. The next earnings report is anticipated on August 10, 2026.

Insider Buying and Selling at Prenetics Global Limited

On June 15, 2026, David Vanderveen bought 6,944 shares and sold 8,681 shares, while Cheng Yin Pan acquired 15,873 shares and sold the same amount on the same day. Earlier, on May 26, 2026, Cheng Yin Pan purchased 6,406 shares. Additionally, on May 19, 2026, Lo Hoi Chun, the Chief Financial Officer, bought 91,629 shares.

Analysts Set New Price Targets

On June 16, 2026, Benchmark initiated coverage on Prenetics Global Limited with a 'buy' rating and a $30 price target. The consensus among analysts is a 'strong buy' recommendation, with an average price target of $31.25, based on four analyst opinions.

About Prenetics Global Limited

Prenetics Global Limited is a healthcare company based in Quarry Bay, Hong Kong, focusing on consumer health sciences. It develops science-backed products under the IM8 brand and operates CircleDNA, a consumer genetic testing service. Founded in 2014, Prenetics aims to enhance human health and longevity. The company is led by CEO Mr. Sheng Wu Yeung and employs about 98 people.

Bottom Line

Cheng Yin Pan's purchase of shares in Prenetics Global Limited suggests confidence in the company's future. Investors often track insider transactions like these for potential insights, though it's important to remember these filings reflect past actions and may not indicate current positions. Prenetics continues to draw attention with its innovative health solutions and active institutional interest.